DCC4526 |
Rvd2n-3 Dpa |
Natural potent macrophage uptake enhancer of S. aureus and zymosan A bioparticles |
|
DCC4527 |
Rwj50271 |
Inhibitor of LFA-1/ICAM-1 Mediated Cell Adhesion |
|
DCC4528 |
Rwj-51204 |
Potent and selective of the benzodiazepine site on GABA(A) receptors |
|
DCC4529 |
rwj-58259 |
Selective antagonist of protease activated receptor-1 |
|
DCC4530 |
Rwj-60475 |
Novel CD45 phosphatase inhibitor |
|
DCC4531 |
Rx-111 |
Novel small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), exercising broad spectrum anti-inflammatory activity by inhibition of protein binding to the cell surface GAG, heparan sulfate |
|
DCC4532 |
Rxfp3/4-agonist-1 |
The first Small Molecule RXFP3/4 Agonist, Increasing Food Intake in Rats Upon Acute Central Administration |
|
DCC4533 |
Ryl-634 |
Novel potent broad-spectrum antiviral inhibitor, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis c virus (HCV), dengue virus (DENV), zika virus (ZIKV), Chikungunya virus (CHIKV), enterovirus 71 |
|
DCC4534 |
S(-)-8-hydroxy-dpat Hydrobromide [78095-20-2] |
Partial 5-HT1A serotonin receptor agonist |
|
DCC4535 |
S(+)-o-desmethylraclopride Hbr |
Selective D2 dopamine receptor antagonist; Precursor to radiolabeled S-(-)-raclopride |
|
DCC4536 |
S007-1558 |
The most viable GPVI modulator, acting as a potent antithrombotic agent |
|
DCC4537 |
S05014 |
Novel highly effective tyrosinase inhibitor with great potential to be utilized in anti-Parkinsonian syndrome |
|
DCC4538 |
S06-1011 |
Highly Potent and Selective Butyrylcholinesterase (BChE) Inhibitor for Cognitive Improvement and Neuroprotection |
|
DCC4539 |
S06-1031 |
Highly Potent and Selective Butyrylcholinesterase (BChE) Inhibitor for Cognitive Improvement and Neuroprotection |
|
DCC4540 |
S07662 |
Inverse agonist of the constitutive androstane receptor (CAR) |
|
DCC4541 |
S-1033 |
FP receptor agonist |
|
DCC4542 |
S-1360 |
Novel HIV-1 integrase inhibitor |
|
DCC4543 |
s14161 |
Novel inhibitor of D-cyclin transactivation via phosphoinositide 3-kinase pathway |
|
DCC4544 |
S14671 |
Potent 5-HT1A receptor agonist, also acting as a 5-HT2A and 5-HT2C receptor antagonist |
|
DCC4545 |
S15535 |
Potent, orally active, partial 5-HT1A receptor agonist |
|
DCC4546 |
s17834 |
Inhibitor of NADPH oxidase, preventing the structural and functional sequelae of diet-induced metabolic heart disease |
|
DCC4547 |
S-18326 |
Potent and selective thrombin inhibitor for the treatment of thromboembolic disorders |
|
DCC4548 |
S18327 |
Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic Receptors |
|
DCC4549 |
S18616 Hydrochloride |
Selective and highly potent alpha2-adrenoceptor agonist |
|
DCC4550 |
S1pr4-agonist-5c |
Novel potent and selective agonist activity for S1PR4 |
|
DCC4551 |
S1r-in-10 |
Novel selective sigma 1 receptor (S1R) antagonist, exhibiting potent binding affinity for S1R, high selectivity over S2R and 87 other human targets, acceptable in vitro metabolic stability, slowing clearance in liver microsomes, and excellent blood-brain |
|
DCC4552 |
S23515 Hydrochloride |
Potent and selective ligand of imidazoline 1 receptor (I1R) |
|
DCC4553 |
S23757 |
Potent and selective ligand of imidazoline 1 receptor (I1R) |
|
DCC4554 |
S27847 |
Potent activator of the AMP-activated protein kinase (AMPK) |
|
DCC4555 |
S32797 |
Potent quinone reductase 2 (QR2) inhibitor |
|